(NASDAQ:IMDX), NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan Healthcare Conference. LifeSci Advisors 15th Annual Corporate Access Event Date: Monday, January […]
(NASDAQ:DH), FRAMINGHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that its Chief Financial Officer, Casey Heller, will present at the 28th Annual Needham Growth Conference. The Definitive Healthcare presentation is scheduled for Wednesday, January 14, 2026, at 9:30 a.m. Eastern
(NASDAQ:RARE), NOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 44th Annual J.P.
(NasdaqGM:STRO), SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026,
(NASDAQ:KRYS), PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company's multi-center, dose escalation Phase 1 study evaluating KB407 in
(NasdaqGM:FLY), SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Firefly Aerospace Inc. (NASDAQ: FLY): (i) securities between August 7, 2025 and September 29, 2025, inclusive (the “Class Period”); and/or (ii) common stock pursuant and/or traceable to Firefly Aerospace's offering documents issued in connection
(NYSE:CXT), WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) — Crane NXT, Co. (NYSE: CXT), a premier industrial technology company, announced that Aaron Saak, President and Chief Executive Officer, and Christina Cristiano, Senior Vice President and Chief Financial Officer, will participate in a fireside chat at the CJS Securities 26th Annual New Ideas for the New
(NYSE:ETD), DANBURY, CT, Jan. 07, 2026 (GLOBE NEWSWIRE) — Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD) will release its financial and operational results for the fiscal 2026 second quarter ended December 31, 2025, after the stock market closes on Wednesday, January 28, 2026. Following the release, the Company will host a
(Paris:ABVX),(NasdaqGM:ABVX), Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD space ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire January 07, 2026 FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to